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340 CorrespondenceLeptotrichia spp are typically large, fusiform-shaped,
non-sporulating, and non-motile rods.4 More recently, based
upon 16S rRNA sequencing, the genus Leptotrichia is
believed to be one of the six genera in the family Fusobac-
teriaceae in the phylum Fusobacteria.4 The primary habitat
of L. buccalis is most likely the human oral cavity, typically
dental plaque. As with the other oral flora, isolation of L.
buccalis from these sites might be indicative of its role in
periodontal disease or oral cavity abscesses.5 Systemic
infections are infrequent and mostly confined to patients
with hematological malignancies and bone marrow trans-
plant recipients, with neutropenia being the common under-
lying factor.6 Because of its recent classification as a
Fusobacterium spp, we think that there should be awareness
of the possibility of Lemierre syndrome in patients with
Leptotrichia bacteremia.
It remains difficult to link the clinical features of our
patient and the sole L. buccalis. Given the fact that the
origin of the infection remains the tonsils in our case, where
mixed anaerobes are the rule, it is possible to detect sec-
ondary organisms as incidental findings that have leaked into
the bloodstream. Indeed, in a significant proportion of cases
in which F. necrophorum is isolated, other organisms are
found. It is rare in the cases of classical Lemierre syndrome.
In our case, we cannot exclude the possibility of F. necro-
phorum infection. Indeed, F. necrophorum could have been
present in our patient, but undetected. A PCR study of a
typical case of Lemierre syndrome in which cultures were
negative detected F. necrophorum DNA.7 This observation
raises the possibility that this may be the cause in other
culture-negative cases or even cases with organisms other
than Fusobacterium spp isolated. We cannot exclude the
possibility of concomitant bacteria such as Fusobacterium
spp even though it was not detected. In our case, we did not
perform PCR on a blood sample to prove infection with
Fusobacterium.
In summary, L. buccalis bacteremia, although uncommon,
could be associated with post-anginal sepsis. This syndrome
should be kept in mind, and CT scans of the neck or Doppler
ultrasound should be performed to assess the diagnosis of
venous jugular thrombosis.
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child with resistant fever and hepatosplenome-
galy due to cytomegalovirus infection. Who and
when to treat?
Primary cytomegalovirus (CMV) infections in immunocompe-
tent humans are self-limited infections from which patients
generally recover without any medical intervention.1,2 How-
ever, CMV infections can be seen with various clinical pre-
sentations in newborns. CMV is the most common congenital
viral infection, occurring in 0.4—2.3% of all live births, and is
probably a common cause of mental retardation and non-
hereditary sensorineural deafness in children.3
Postnatally-acquired CMV infection in immunocompetent
patients is generally subclinical but may sometimes give rise
to a mild and self-limited mononucleosis-like syndrome.4The occurrence of CMV disease in transplant recipients and
patients with AIDS is well described. CMV can cause severe
pneumonitis, hepatitis, chorioretinitis, iridocyclitis, and
pancreatitis with possible life-threatening multi-organ man-
ifestations in immunocompromised persons.5—7 We present
herein the case of a 30-month-old immunocompetent girl
with severe CMV infection with multiple organ involvement,
who was successfully treated with ganciclovir.
A previously healthy 30-month-old girl was admitted to our
hospital with fever, diarrhea, and abdominal distention of
three-month duration. She was born of a healthy mother at
39 weeks of gestation (birth weight 2800 g) and had been
breastfed for 4 months; at the age of 21 months, she had
startedattendingadaycarecenter.Her temperatureonadmis-
sion was 38.5 8C, her heart ratewas 110 beats perminute, and
her blood pressure was 100/60 mmHg. Physical examination
Correspondence 341revealed abdominal distension and hepatosplenomegaly (the
size of her liver was 10 cm and spleen was 7 cm at the mid-
clavicular line). Laboratory tests showed mild hypochromic
microcytic anemia with a hematocrit of 25.4%, hemoglobin of
8.7 g/dl, and a normal platelet count (316  109/l). The total
white blood cell count was 11.7  109/l with 28% segmented
granulocytes, 54% lymphocytes, and 18% monocytes with 7%
band formation. Bone marrow aspiration revealed megalo-
blastic changes, increased numbers of histiocytes, vacuoliza-
tion in erythrocytes, and myeloid series. The erythrocyte
sedimentation rate was 28 mm/h (normal: 0—10) and C-reac-
tive protein level was 3.25 mg/dl (normal: 0—0.8 mg/dl). Her
biochemical parameters were 42 U/L AST (upper normal:
<40 U/L) and 34 U/L ALT (upper normal: <40 U/L). Her
immunoglobulin levels including IgG, IgM, and IgA were all
within the normal range. A peripheral blood smear for plas-
modium was normal. Sequential cultures of blood, urine, and
bone marrow were negative for tuberculosis bacilli, salmo-
nellosis, brucellosis, leishmaniasis, and other bacterial and
fungal infectious diseases. Serology for hepatitis A, B, C, HIV,
parvovirus, Toxoplasma, Salmonella, and Epstein—Barr virus
(EBV) infections were all negative. CMV IgM and CMV IgG were
positive. The CMV PCR in blood samples (plasma CMV PCR) was
8260 copies/ml while in urine the CMV viral PCR was
1740 copies/ml. Laboratory tests from the mother showed
her to be CMV specific IgG-positive. Abdominal ultrasonogra-
phy revealed hyperechogenic lesions that suggested a heman-
gioma with 1.5 cm diameter in the left lobe of the liver and
hepatosplenomegaly. A liver biopsy showed rare mononuclear
cells in the portal area, necrosis in two sections, and a few
inflammatory cells, but no CMV inclusions were seen. Due to
the child’s deteriorating state, ganciclovir therapy was
initiated (10 mg/kg/day in two divided doses) and continued
for 21 days. On the 5th day of therapy the fever had resolved
and on the 14th day hepatosplenomegaly had significantly
resolved. Ganciclovir was well tolerated in our patient and
she did not experience toxicity. After completion of the ther-
apy, both urine and blood PCR samples were CMV-negative.
During her follow-up, sixth months and one year later, she had
no fever and no hepatosplenomegaly. Her blood CMV PCR was
negative.
Primary CMV infections rarely give rise to clinical illness in
immunocompetent persons. CMV causes a mononucleosis-
like syndrome with clinical features such as prolonged fever,
myalgia, and cervical lymphadenopathy. EBV and early HIV
infections should be differentiated in such a case.4,8,9 Several
complications or associated manifestations such as biochem-
ical or clinical hepatitis, skin rash, colitis, pneumonitis,
adrenalitis, myocarditis, and, rarely, encephalitis or other
involvement of the central nervous system (CNS) have been
described in immunocompetent patients with CMV infec-
tion.10 Although it is extremely rare, severe and even fatal
CMV infections have been reported.2 Faucher et al.11 per-
formed a retrospective analysis of 116 adult hospitalized
patients and outpatients, and reported that fever was
noted in 99% of patients, with a mean duration of 21 days.
Fifty-one percent of those patients had headache, 46% had
myalgia, and 36% had splenomegaly. Respiratory and neuro-
logical symptoms were noted in 8% and 1% of patients,
respectively.
Almost all reported cases of CMV infections in immuno-
competent patients have been self-limiting, although therehave been some sporadic cases, our case included, where the
clinical condition is prolonged and there is deterioration for
which treatment might be needed, despite an effective
immune system. In this group of patients, treatment indica-
tions are still not clearly defined. Since primary CMV infection
in immunocompetent hosts is generally self-limited, no spe-
cific antiviral therapy is usually required. However, antiviral
therapy can be beneficial in immunocompetent hosts, includ-
ing adults with severe acute or persistent CMV infection, as
reported in a limited number of cases.12,13
Antiviral drugs, such as ganciclovir are available for CMV
infection, but they are licensed for use only in severe or life-
threatening illness in immunocompromised patients.14,15 The
efficacy of ganciclovir therapy in children with CMV infection
remains controversial. Ganciclovir, a guanosine analog,
selectively inhibits CMV DNA polymerase, and it is the anti-
viral drug used to treat immunocompromised patients such as
transplant recipients and AIDS patients with active CMV
infection.13 A study concerning CNS infections due to CMV
reported that nearly two thirds of patients in the pediatric
age group treated with ganciclovir developed neutropenia.16
Although it is not shown in humans, ganciclovir has both
gonadal toxicity and carcinogenicity in animal models.17
Foscarnet is the only anti-herpes drug that is not a nucleo-
side or nucleotide analogue. Foscarnet inhibits all known
human herpesviruses, including acyclovir-resistant herpes
simplex virus and varicella zoster virus strains and most
ganciclovir-resistant CMV isolates. Foscarnet is associated
with significant renal toxicity, and it is not the drug of choice
for CMV.18
The prodrug, valganciclovir, an orally well-absorbed ester
of ganciclovir and the amino acid L-valine, was developed to
increase the bioavailability of ganciclovir. In adults it
achieves ganciclovir plasma concentrations similar to those
with intravenous ganciclovir. The high bioavailability and
convenient dosing formulation make valganciclovir an attrac-
tive option. However, though carried out in adults, there
have been no safety and efficacy trials of valganciclovir in
children;19,20 pharmacokinetics and safety issues still need to
be resolved in children. Valganciclovir is likely to be an
alternative oral treatment that can be prospectively studied
in children.
In our case, due to the prolonged severe clinical picture
and deterioration, treatment of the CMV infection with
ganciclovir was started and was continued for 21 days; the
patient responded to this therapy dramatically and the
hepatosplenomegaly decreased remarkably. After therapy,
CMV PCR became negative. Our patient’s clinical outcome
and response to ganciclovir therapy was similar to that
reported by Hadaya et al. in a 17-month-old girl who also
responded to short-course (5 days) ganciclovir therapy.21
CMV is transmitted vertically (from mother to infant,
before, during, or after birth), horizontally (by direct per-
son-to-person contact with virus-containing secretions espe-
cially in daycare centers and via breastfeeding in children),
and via transfusions of blood products. Breastfeeding signifi-
cantly influences the epidemiology of postnatal human CMV
infection.23 The virus was isolated from human milk more
than 30 years ago, but the roles of milk cells and cell-free
virus in transmission have remained unclear.24 Several studies
have investigated shedding of CMV into breast milk and
transmission to term infants.24 The low socioeconomic status
342 Correspondenceof our patient and the history of being cared for in a crowded
daycare center could suggest the second route of transmis-
sion (by direct person-to-person contact at the daycare
center) as has previously been described.22 We considered
out case to be a primary CMV infection because the complaint
occurred after she had started attending daycare, but we
could not exclude reactivation of congenital CMV.
In conclusion, immunocompetent persons usually recover
spontaneously from CMV infections, but in exceptional cases
like in our patient with prolonged fever, deteriorating state,
and hepatosplenomegaly, ganciclovir therapy might be ben-
eficial. Currently, due to the known possible side effects of
ganciclovir therapy, it is indicated only in limited conditions,
notably in immunocompromised patients. However, in immu-
nocompetent patients with an unstable or clinically deterior-
ating condition, ganciclovir might also be considered as a
treatment option.
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